NGEN
HEALTHCARENANOGEN INC
Live · NASDAQ · May 9, Close
What's Moving NGEN Today?
No stock-specific AI insight has been generated for NGEN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.89
Fundamentals
Trading
NGEN News
13 articles- NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial OfficerYahoo Finance·Apr 27, 2026
- NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceYahoo Finance·Apr 13, 2026
- NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic TetraplegiaYahoo Finance·Apr 7, 2026
- The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsightGlobeNewswire Inc.·Apr 2, 2026
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 31, 2026
- NervGen Pharma Announces Voluntary Delisting from TSX Venture ExchangeYahoo Finance·Mar 12, 2026
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical AffairsYahoo Finance·Mar 4, 2026
- NervGen Pharma to Participate at Upcoming Investor ConferencesYahoo Finance·Feb 18, 2026
- NervGen Pharma Announces Retirement of Chief Financial Officer, Bill AdamsYahoo Finance·Feb 12, 2026
- NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy SymposiumYahoo Finance·Feb 11, 2026
- NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord InjuryYahoo Finance·Feb 9, 2026
- When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven?Yahoo Finance·Feb 1, 2026
- NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq ListingYahoo Finance·Jan 20, 2026
All 13 articles loaded
Price Data
52-Week Range
$3.89
Fundamentals
Trading
About NANOGEN INC
Nanogen Inc (NGEN) is a cutting-edge biotechnology company dedicated to advancing molecular diagnostic technologies aimed at improving patient outcomes through innovative genomic analysis solutions. The firm specializes in the development and commercialization of products tailored to complex disease targets, utilizing its proprietary platforms to deliver precise and timely diagnostics. With a robust focus on research and development, Nanogen is poised to expand its portfolio and drive growth in the dynamic diagnostic market, aligning with the industry's shift toward personalized medicine and the increasing demand for sophisticated diagnostic tools.